A detailed history of Candriam S.C.A. transactions in Kura Oncology, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 906,482 shares of KURA stock, worth $9.05 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
906,482
Previous 906,482 -0.0%
Holding current value
$9.05 Million
Previous $18.7 Million 5.1%
% of portfolio
0.1%
Previous 0.11%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024

BUY
$17.53 - $22.98 $4.47 Million - $5.86 Million
255,065 Added 39.16%
906,482 $18.7 Million
Q1 2024

May 03, 2024

BUY
$13.42 - $23.53 $1.48 Million - $2.59 Million
110,000 Added 20.32%
651,417 $13.9 Million
Q4 2023

Feb 14, 2024

SELL
$7.58 - $14.38 $1.14 Million - $2.16 Million
-150,005 Reduced 21.7%
541,417 $7.79 Million
Q2 2023

Aug 08, 2023

SELL
$9.62 - $13.99 $1.18 Million - $1.72 Million
-122,942 Reduced 15.1%
691,422 $7.32 Million
Q4 2022

Feb 13, 2023

BUY
$11.23 - $16.9 $1.33 Million - $2.01 Million
118,789 Added 17.08%
814,364 $10.1 Million
Q3 2022

Nov 10, 2022

BUY
$12.01 - $19.45 $3.09 Million - $5 Million
257,260 Added 58.69%
695,575 $9.5 Million
Q1 2022

May 13, 2022

SELL
$11.78 - $16.98 $5.53 Million - $7.97 Million
-469,118 Reduced 51.7%
438,315 $7.05 Million
Q4 2021

Feb 10, 2022

SELL
$12.22 - $19.57 $475,651 - $761,742
-38,924 Reduced 4.11%
907,433 $12.7 Million
Q2 2021

Jul 20, 2021

BUY
$20.85 - $29.88 $356,118 - $510,350
17,080 Added 1.84%
946,357 $19.7 Million
Q1 2021

Apr 29, 2021

SELL
$24.75 - $39.14 $123 - $195
-5 Reduced -0.0%
929,277 $29.2 Million
Q4 2020

Jan 22, 2021

BUY
$29.0 - $41.62 $11.3 Million - $16.2 Million
390,086 Added 72.35%
929,282 $30.4 Million
Q3 2020

Oct 19, 2020

BUY
$16.3 - $30.64 $4.88 Million - $9.18 Million
299,492 Added 124.94%
539,196 $16.5 Million
Q2 2020

Jul 23, 2020

BUY
$7.95 - $18.81 $1.91 Million - $4.51 Million
239,704 New
239,704 $3.91 Million
Q4 2019

Jan 21, 2020

SELL
$12.97 - $15.94 $1.79 Million - $2.2 Million
-138,100 Closed
0 $0
Q3 2019

Oct 21, 2019

SELL
$14.75 - $20.87 $3.3 Million - $4.67 Million
-224,000 Reduced 61.86%
138,100 $2,000
Q2 2019

Aug 01, 2019

SELL
$14.71 - $19.79 $498,669 - $670,881
-33,900 Reduced 8.56%
362,100 $7.1 Million
Q1 2019

May 02, 2019

BUY
$13.73 - $16.87 $411,900 - $506,100
30,000 Added 8.2%
396,000 $6.57 Million
Q3 2018

Nov 07, 2018

SELL
$16.65 - $21.85 $266,400 - $349,600
-16,000 Reduced 4.19%
366,000 $6.41 Million
Q2 2018

Aug 14, 2018

SELL
$14.8 - $18.8 $44,400 - $56,400
-3,000 Reduced 0.78%
382,000 $6.95 Million
Q1 2018

May 09, 2018

SELL
$14.5 - $23.4 $1.89 Million - $3.04 Million
-130,000 Reduced 25.24%
385,000 $7.22 Million
Q4 2017

Feb 07, 2018

SELL
$13.5 - $16.65 $337,500 - $416,249
-25,000 Reduced 4.63%
515,000 $7.88 Million
Q3 2017

Nov 03, 2017

BUY
$6.05 - $14.95 $3.27 Million - $8.07 Million
540,000
540,000 $8.07 Million

Others Institutions Holding KURA

About Kura Oncology, Inc.


  • Ticker KURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,893,000
  • Market Cap $668M
  • Description
  • Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...
More about KURA
Track This Portfolio

Track Candriam S.C.A. Portfolio

Follow Candriam S.C.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.